Single-Use Bioreactors

REPORT HIGHLIGHTS

Global Single-Use Bioreactors Market to Reach US$16.0 Billion by 2032

The global market for Single-Use Bioreactors estimated at US$5.3 Billion in the year 2025, is expected to reach US$16.0 Billion by 2032, growing at a CAGR of 16.9% over the analysis period 2025-2032. Stirred-Tank Product Type, one of the segments analyzed in the report, is expected to record a 19.2% CAGR and reach US$6.6 Billion by the end of the analysis period. Growth in the Wave-Induced Product Type segment is estimated at 13.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 23.2% CAGR

The Single-Use Bioreactors market in the U.S. is estimated at US$1.6 Billion in the year 2025. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.6 Billion by the year 2032 trailing a CAGR of 23.2% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.6% and 15.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.8% CAGR.

Global Single-Use Bioreactors Market - Key Trends and Drivers Summarized

Why Are Single-Use Bioreactors Becoming a Game-Changer in Biomanufacturing?
Single-use bioreactors are becoming a game-changer in biomanufacturing due to their ability to provide flexible, cost-effective, and scalable solutions for producing biologics, vaccines, and cell and gene therapies. Unlike traditional stainless-steel bioreactors, single-use bioreactors (SUBs) use disposable bags and components, which minimize the risk of cross-contamination, reduce cleaning and sterilization requirements, and accelerate turnaround times. These benefits are particularly valuable for biopharmaceutical companies involved in multi-product, small-batch, or early-phase production, where agility and speed to market are critical. As the demand for biologics continues to grow, single-use bioreactors are emerging as a preferred choice for upstream bioprocessing in both clinical and commercial manufacturing.

How Are Technological Innovations Enhancing the Utility of Single-Use Bioreactors?
Technological innovations are enhancing the utility of single-use bioreactors by improving their scalability, control, and integration with other bioprocessing systems. The development of high-density, low-shear, and fully automated single-use bioreactors is enabling more efficient and robust cell culture processes for producing monoclonal antibodies, vaccines, and cell therapies. Advances in disposable sensors, monitoring systems, and control algorithms are enhancing process control, data integrity, and reproducibility, making single-use bioreactors more reliable and user-friendly. Additionally, the integration of single-use bioreactors with continuous processing, perfusion systems, and modular facilities is optimizing biomanufacturing by reducing costs, increasing productivity, and ensuring compliance with regulatory standards. These innovations are driving the adoption of single-use bioreactors across various biopharma applications.

Which Market Segments Are Leading the Adoption of Single-Use Bioreactors?
Types of single-use bioreactors include stirred-tank, wave-mixed, and hybrid bioreactors, with stirred-tank bioreactors being the most widely used due to their versatility, scalability, and compatibility with existing bioprocesses. Applications of single-use bioreactors span monoclonal antibody production, vaccine development, cell and gene therapy, biosimilars, and microbial fermentation, with monoclonal antibody production leading the market due to the high demand for biologics. End-users include biopharmaceutical companies, CDMOs, and academic and research institutions, with biopharmaceutical companies being the primary adopters due to their focus on efficient and scalable production processes. Geographically, North America and Europe are the largest markets for single-use bioreactors due to strong biopharma infrastructure, technological advancements, and regulatory support, while Asia-Pacific is emerging as a high-growth region driven by expanding biopharma capacity and increasing investments in biologics.

What Are the Key Drivers of Growth in the Single-Use Bioreactors Market?
The growth in the single-use bioreactors market is driven by several factors, including the rising demand for flexible, scalable, and cost-effective biomanufacturing solutions, technological advancements in high-density, low-shear, and fully automated single-use bioreactors, and the increasing use of single-use bioreactors in monoclonal antibody production, vaccine development, and cell and gene therapy. The development of customizable, integrated, and modular single-use bioreactor platforms is driving market adoption among biopharmaceutical companies, CDMOs, and academic institutions. The focus on reducing cross-contamination, cleaning validation, and capital expenditure is expanding the market reach among multi-product, small-scale, and flexible manufacturing facilities. The growing use of single-use bioreactors in upstream bioprocessing, coupled with the demand for energy-efficient, eco-friendly, and sustainable solutions, is creating new opportunities for market growth. Additionally, the increasing investments in R&D for advanced sensors, controllers, and monitoring systems are further supporting market expansion.

SCOPE OF STUDY:

The report analyzes the Single-Use Bioreactors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Stirred-Tank Product Type, Wave-Induced Product Type, Bubble-Column Product Type, Other Product Types); Cell Type (Mammalian Cell Type, Bacterial Cell Type, Yeast Cell Type, Other Cell Types); Molecule Type (Monoclonal Antibodies Molecule Type, Vaccines Molecule Type, Gene Modified Cells Molecule Type, Stem Cells Molecule Type, Other Molecule Types); Application (R&D Application, Bioproduction Application); End-Use (Pharma & Biopharma Companies End-Use, CROs & CMOs End-Use, Academic & Research Institutes End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

• Applikon Biotechnology BV
• Cellexus Ltd.
• Celltainer Biotech B.V.
• Cesco Bioengineering Co. Ltd.
• Danaher Corporation
• Distek, Inc.
• Eppendorf AG
• GE Healthcare
• PBS Biotech, Inc.
• Sartorius AG

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more